Background: Ferroptosis which is a unique type of regulated cell death, has been featured as an urgent mechanism in
development and progression of cancer, especially regarding the resistance to chemotherapy.
Subjects and methods: This retrospective study involved immunohistochemical analysis of SLC7A11, ACSL4,
HNRNPA2B1, and YTHDF1 expression in 95 cases of invasive ductal carcinoma of the breast, all had been treated
with neoadjuvant chemotherapy.
Results: Positive expression of SLC7A11 was identified in 63.2% of cases and demonstrated a statistically significant
linear association with tumor grade, clinical tumor stage, clinical lymph node (LN) stage, postoperative pathological
tumor and nodal staging and molecular subtypes. High expression of ACSL4 was observed in 51.6% of cases and
demonstrated a statistically significant inverse relationship with tumor grade, clinical tumor staging, clinical
lymph node (LN) staging, and postoperative pathological tumor and nodal staging. Positive HNRNPA2B1
expression was apparent in 64.2% of cases and exhibited a statistically significant relationship with tumor grade,
clinical tumor staging, clinical LN staging, pathological tumor and nodal staging (postoperative) and molecular type.
High expression of YTHDF1 was apparent in 62.1% of cases and exhibited statistically significant relationship with
tumor grade, clinical tumor staging, clinical LN staging, pathological tumor and nodal staging. Pathological complete
response (pCR) was significantly frequent in cases with early clinical tumor and nodal stage, negative SLC7A11
expression (ferroptosis inhibitor), high ACSL4 level (ferroptosis inducer), negative HNRNPA2B1 and low YTHDF1
expression |
